The tumor microenvironment (TME) imposes major barriers to CAR-NK cells’ efficacy, including immunosuppressive cytokines (e.g., TGF-β, IL-10), metabolic constraints such as hypoxia and adenosine accumulation, and immune checkpoints like PD-L1. The gene discussed is CD274; the disease is neoplasm.